Nicotinic receptors in the brain modulate the release of many transmitters that are known to regulate voiding. This prompted us to examine the central nervous system effects of a neuronal nicotinic agonist, ( )-epibatidine, on voiding function in awake and anesthetized rats. Intracerebroventricular (i.c.v.) injection of ( )-epibatidine (0.1 µg) significantly increased intercontraction interval (ICI), but did not change pressure threshold (PT), or maximal voiding pressure (MVP); whereas 1 µg of ( )-epibatidine increased PT, MVP (P<0.05) and decreased ICI. A low i.v. dose of ( )-epibatidine (0.001-0.1 µg) had no effect; however, a large dose of ( )-epibatidine (1 g The experiments revealed that activation of nicotinic receptors in the brain increased bladder capacity in awake and anesthetized rats. These results suggest that the nicotinic agonist can activate mechanism that inhibit voiding reflexes.
INTRODUCTION
Cholinergic mechanisms are involved at various sites in the neural pathways controlling voiding function. In the peripheral nervous system acetylcholine is the major excitatory transmitter at: (a) the parasympathetic neuroeffector junction in the bladder, (b) in sympathetic and parasympathetic ganglia and (c) at the neuromuscular junction in urethral striated muscle (6, 12) . In the bladder the effects of acetylcholine are mediated by muscarinic receptors, whereas in ganglia and at the neuromuscular junction nicotinic receptors are involved (5) .
Experimental studies in animals have raised the possibility that acetylcholine is also a transmitter in the central neural pathways controlling bladder activity. Injections of cholinergic agonists into the region of pontine micturition center in cats elicited inhibition or excitation depending the site of the injection (21) . The effects were antagonized by atropine indicating a role of muscarinic receptors. Administration of bethanechol, a muscarinic agonist to the brain of the dog by a vascular cross perfusion technique reduced bladder capacity and increased maximal voiding pressure (14) . In the rat, intracerebroventricular (i.c.v.) injection of oxotremorine-M, a muscarinic agonist, elicited both inhibitory and excitatory effects that were blocked by atropine (9) . I.c.v. administration of atropine alone decreased maximal voiding pressure and increased bladder capacity indicating that excitatory mechanisms are tonically active in controlling voiding function. Recent experiments revealed that second messenger pathways involving protein kinase C are involved in the central muscarinic inhibitory control of bladder activity in the rat (13) .
The demonstration of central muscarinic cholinergic mechanisms in micturition raises the possibility that nicotinic receptors might also be involved in the control of voiding function. Nicotinic receptors are widely distributed in the central nervous system (20) and have a prominent modulatory effect on various types of synaptic transmission. Activation of nicotinic receptors on presynaptic terminals enhances the release of many transmitters including: norepinephrine, dopamine, glutamic acid, acetylcholine and serotonin (3, 10, 17, 18, 24) all of which have been implicated in the central neural control of bladder function (5).
Administration of nonselective neuronal nicotinic receptor agonists such as nicotine or ( )-epibatidine, exo-2-(6-chloro-3-pyridyl)-7-azabicyclo-[2.2.1] a toxic agent from frog skin, produces prominent changes in central nervous system activity including improvement in cognitive functions, changes in motor behavior, analgesia, nausea and vomiting (4, 11, 22, 25) . Agents with selective nicotinic receptor agonist actions have recently been synthesized (4) and are being evaluated for their efficacy in the treatment of various disorders ranging from Alzheimer's disease, pain to attention deficit hyperactivity disorder (1) .
In the present experiments we examined the role of central nicotinic receptors in micturition by studying the effect of i.c.v. and intravenous (i.v.) administration of the nicotinic agonist, ( )-epibatidine, and the nicotinic antagonist, chlorisondamine, on voluntary and reflex voiding function in awake and anesthetized female rats, respectively.
MATERIALS AND METHODS

Animal preparations
Voiding was studied in urethane anesthetized (1.2 g/kg subcutaneous) or awake female SpragueDawley rats (250 to 300 gm, Hilltop Lab., Scottdale, PA, USA). In the latter group of animals surgery was performed under halothane anesthesia (2% in oxygen). To implant the i.c.v. catheter, the rats were positioned in a stereotaxic frame, a scalp incision was made over the sagittal suture, and a hole (diameter: approximately The urinary bladder was catheterized using the method of Yaksh et al. (26) . The bladder was exposed via a midline abdominal incision. A catheter (PE-50), the bladder end of which was heated to create a collar, was inserted through a small incision in the bladder dome, and a suture was tightened around the collar. The other end of the catheter was passed through subcutaneous tissue and exited through the skin. After closing the abdominal incision by suturing the muscle and skin, rats that were to be studied without anesthesia were placed in a restraining cage for 5-6 h (including 2 h of recovery from halothane) that was large enough to permit them to adopt a normal crouching posture, but narrow enough to prevent them from turning around.
The rats were subsequently allowed to recover from halothane anesthesia.
The bladder catheter was connected via a T-stopcock to a pump for continuous infusion of physiological saline and to a pressure transducer. Physiological saline was infused at room temperature into the bladder at a constant rate of 0.04 ml/min to elicit repeated voiding responses. The volume-evoked micturition reflexes were studied in urethane anesthetized and conscious, restrained rats. All animal care and surgical procedures were approved by the Institutional Animal Care and Use Committee at the University of Pittsburgh.
Evaluation
In all experiments, control cystometrograms (CMG) were recorded for about 2 h prior to i.c.v. and i.v. 
Statistical analysis
A repeated measures one-way analysis of variance with drug dose as the repeated measure was used for analysis of ( )-epibatidine effects. For post hoc analysis, the Bonferroni test was employed. An unpaired student t test was used for analysis of the differences in effects between anesthesized and awake groups. Data are presented as means S.D. P < 0.05 was considered statistically significant.
RESULTS
Effect of ( )-epibatidine via i.c.v. injection in awake rats
In awake rats (n=7) in which voiding parameters were not changed after i. 
Effect of ( )-epibatidine via i.c.v. injection in urethane anesthesized rats
In anesthetized rats (n=4) voiding parameters were not changed after injection of ACSF 4 ).
Effect of ( )-epibatidine via i.v. injection in urethane anesthesized rats and awake rats
I.v. injection of normal saline did not alter any CMG parameter in anesthetized (n=4) or awake rats However the site of action of high doses of ( )-epibatidine which produced a rise in intravesical pressure and reduced the voiding interval is less clear, because large doses of ( )-epibatidine administered i.v.
produced similar effects and chlorisondamine injected i.c.v. was not able to block the effect of ( )-epibatidine. Thus, large i.c.v. doses of ( )-epibatidine might enter the peripheral circulation and stimulate parasympathetic ganglia to induce a bladder contraction. Alternatively, large doses of ( )-epibatidine might act in the central nervous system (CNS) on nAChR which had not been accessed by chlorisondamine due to the relatively short pretreatment time. Chlorisondamine is more hydrophilic than ( )-epibatidine and therefore is likely to require a long time for diffusion throughout the brain. Another concern in interpreting the effect of the large dose of ( )-epibatidine is that this dose induced respiratory changes as well as limb and body movements. Thus, it is possible that changes in intra-abdominal pressure were transmitted to the bladder and this contributed to the apparent facilitatory effect of the drug on voiding.
( )-epibatidine has not only a potent stimulatory effect on nAChR subtypes in the brain (α4β2) but also in sympathetic and parasympathetic ganglia (α3β4) and at the neuromuscular junction (α1β1γδ) (22) .
Thus, the excitatory effects of i.v. injection of ( )-epibatidine (1 g) on voiding function shown by decreased ICI and increased MVP could be due to stimulation of the parasympathetic excitatory input to the bladder as well as stimulation of sympathetic input to the urethral smooth muscle or direct stimulation of nicotinic receptors in the striated muscle of the urethra which would increase outlet resistance. Effects of ( )-epibatidine on peripheral nAChR can also produce hypertension and striated muscle effects both of which limit the clinical use of nicotinic agonists (19, 22) .
Although the CNS site of the inhibitory action of ( )-epibatidine on micturition is uncertain it seems reasonable to conclude that the drug depresses the afferent limb of the micturition reflex in anesthetized rats and depresses the sensory pathways that induce voluntary voiding in awake rats because the drug decreased voiding frequency without altering voiding pressure. If the efferent pathway from the brain to the sacral parasympathetic nucleus or sphincter motor nucleus in the spinal cord were affected by the drug, it would be expected that peak voiding pressure would be changed. The decrease in voiding frequency after ( )-epibatidine could be produced by inhibition of transmission of afferent signals in the spinal cord or inhibition of afferent processing in the brain stem pontine micturition center or in centers in the forebrain involved in voluntary voiding (Fig. 6 ). However, there was no significant difference between the effect of ( )-epibatidine on CMG parameters in urethane anesthetized and awake rats. Since voiding in anesthetized animals is reflex and presumably involves circuitry in the brain stem and spinal cord but is not dependent on forebrain circuits; this raises the possibility that ( )-epibatidine acted on the brain stem to alter voiding in both groups of animals.
Activation of nAChR is known to enhance the release of various CNS transmitters including glutamate, serotonin, norepinephrine, acetylcholine and dopamine (3, 10, 17, 18, 24) . Previous pharmacological studies in animals showed that activation of the receptors for these transmitters in the brain can under certain conditions inhibit voiding function, reduce voiding frequency and increase bladder capacity (7, 23, 27) . and low dose of ( )-epibatidine did not affect the ICI. A moderate dose of ( )-epibatidine increased the ICI, whereas a high dose of ( )-epibatidine (lower trace) induced an initial bladder contraction and decreased the ICI. 
